Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
53 studies found for:    Open Studies | "Hemorrhagic Fevers, Viral"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemorrhagic Fevers, Viral"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Condition: Viral Hemorrhagic Fever
Intervention: Drug: Ribavirin
2 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
3 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
4 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac
Condition: Hemorrhagic Fever, Ebola
Intervention: Procedure: blood sampling collection
5 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
6 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
7 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
8 Recruiting Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine (5 dose formulation);   Biological: Placebo, NaCl 0.9%
9 Recruiting Diagnostic of Puumala Virus Infection in France
Conditions: Nephropathia Epidemica;   Hemorrhagic Fever With Renal Syndrome
Intervention:
10 Recruiting Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Papillomavirus Disease
Interventions: Biological: CYD Dengue Vaccine;   Biological: Human Papillomavirus Bivalent [Types16 and 18] Vaccine, Recombinant.;   Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant.
11 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
12 Recruiting GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Condition: Persistent Ebola Virus
Interventions: Drug: GS-5734;   Other: Placebo Comparator
13 Recruiting Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen
Condition: Ebola Virus Survivor
Intervention: Drug: Favipiravir
14 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
15 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
16 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
17 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
18 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
19 Not yet recruiting Repeatability and Reproducibility of the ArcScan Insight 100 VHF Digital Ultrasound
Conditions: Corneal Thickness Measurement;   Epithelial Thickness Measurement;   Anterior Eye Segment Measurements
Intervention: Device: ArcScan Insight 100 very high-frequency digital ultrasound
20 Not yet recruiting MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
Conditions: Marburg Disease;   Ebola Disease
Interventions: Biological: MVA Multi-Filo Ebola Vaccine;   Biological: Ad26 Zaire Ebola Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.